About Applied Therapeutics
Applied Therapeutics (NASDAQ:APLT) focuses on developing novel treatments in areas where there is a significant unmet medical need. With a dedicated team of experienced professionals, the company is currently advancing a pipeline of therapeutic candidates aimed at addressing conditions in metabolic diseases, diabetic complications, and neurodegenerative diseases. Their approach combines innovative science with a deep understanding of the diseases they aim to treat, striving to bring transformative therapies to patients who currently have limited or no treatment options. Central to their mission is a commitment to rigorous scientific methodologies and patient safety, underscoring their goal to improve lives through groundbreaking medical advancements.
Snapshot
Operations
Products and/or services of Applied Therapeutics
- AT-007, a central nervous system penetrant Aldose Reductase inhibitor for Galactosemia.
- AT-001, an aldose reductase inhibitor for diabetic cardiomyopathy.
- AT-003, an ARI designed for the treatment of diabetic retinopathy.
- Development of novel therapies targeting rare diseases with high unmet medical need.
- Exploration of AT-007's effectiveness in SORD Deficiency, a metabolic disorder.
Applied Therapeutics executive team
- Mr. Les D. FuntleyderInterm CEO, CFO, Principal Financial Officer & Director
- Mr. Corwin Dale HooksChief Commercial Officer
- Mr. Constantine ChinoporosCOO & Chief Business Officer
- Ms. Catherine ThorpeInterim Chief Accounting Officer
- Ms. Reena Thomas ColacotHead of Quality
- Dr. Todd F. Baumgartner M.D., M.P.H.Chief Regulatory Officer
- Dr. Evan Prescott Bailey M.D.Chief Medical Officer
- Ms. Dottie CaplanExecutive Vice President of Patient Advocacy & Government Affairs.